Recurrent Crow-Fukase syndrome associated with increased serum levels of vascular endothelial growth factor: A case report and review of the literature

被引:26
作者
Mineta, Mitsuyoshi
Hatori, Masahito
Sano, Hirotaka
Hosaka, Masami
Kokubun, Shoichi
Hiroki, Eri
Hatakeyama, Akira
Ogasawara, Tetsuro
机构
[1] Tohoku Univ, Sch Med, Dept Orthopaed Surg, Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Tohoku Rosai Hosp, Dept Rheumatol, Sendai, Miyagi, Japan
[3] Tohoku Rosai Hosp, Dept Internal Med, Sendai, Miyagi, Japan
关键词
Crow-Fukase syndrome; vascular endothelial growth factor (VEGF); polyneuropathy;
D O I
10.1620/tjem.210.269
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Crow-Fukase syndrome (CFS) is a rare multi-system disorder, characterized by polyneuropathy, organomegaly, endocrinopathy, M-proteins, skin changes and anasarea, with or without myeloma. The pathophysiology, diagnosis, and treatment of CFS are controversial. CFS may be associated with the overproduction of vascular endothelial growth factor (VEGF). However, there have been no reports of monitoring the serum VEGF level after recurrence, to the best of our knowledge. We report a 54-year-old man with CFS presenting with a 3-year history of ascites, anasarca, weakness of the lower extremities, and plasmacytoma in the scapula. At the initial examination, the VEGF level was 1,590 pg/ml (the VEGF level of a healthy control, 78.4 +/- 75.2 pg/ml). After initial treatment with chemotherapy and irradiation of the affected shoulder, the VEGF level decreased to 154 pg/ml and the symptoms disappeared. Twenty one months later, gate disturbance and anasarca recurred, and the VEGF level was over 2,000 pg/dl. After total scaplectomy, the VEGF level decreased to 730 pg/dl and the symptoms disappeared. The serum level of VEGF well correlated to the clinical course of the patient. In conclusion, measurement of the VEGF level is useful for diagnosing CFS and for monitoring its clinical course.
引用
收藏
页码:269 / 277
页数:9
相关论文
共 49 条
[1]   Crow-fukase syndrome associated with high-output heart failure [J].
Araki, T ;
Konno, T ;
Soma, R ;
Nakashima, A ;
Takimoto, H ;
Tofuku, Y ;
Shimizu, M .
INTERNAL MEDICINE, 2002, 41 (08) :638-641
[2]  
Arimura H, 1997, Rinsho Shinkeigaku, V37, P817
[3]  
ARMIMURA K, 2003, SHINKEI SHINPO, V47, P545
[4]   No nephropathy in Type 2 diabetic patient with POEMS syndrome with an elevated plasma VEGF [J].
Baba, T ;
Osterby, R ;
Neugebauer-Baba, S ;
Nozawa, Y ;
Watanabe, T ;
Sakurai, K ;
Katoh, T ;
Watanabe, T .
DIABETIC MEDICINE, 2004, 21 (03) :292-294
[5]   Bevacizumab therapy for POEMS syndrome [J].
Badros, A ;
Porter, N ;
Zimrin, A .
BLOOD, 2005, 106 (03) :1135-1135
[6]   PLASMA-CELL DYSCRASIA WITH POLYNEUROPATHY, ORGANOMEGALY, ENDOCRINOPATHY, M PROTEIN, AND SKIN CHANGES - THE POEMS SYNDROME - REPORT ON 2 CASES AND A REVIEW OF THE LITERATURE [J].
BARDWICK, PA ;
ZVAIFLER, NJ ;
GILL, GN ;
NEWMAN, D ;
GREENWAY, GD ;
RESNICK, DL .
MEDICINE, 1980, 59 (04) :311-322
[7]   EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) BY EPIDERMAL-KERATINOCYTES DURING WOUND-HEALING [J].
BROWN, LF ;
YEO, KT ;
BERSE, B ;
YEO, TK ;
SENGER, DR ;
DVORAK, HF ;
VANDEWATER, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (05) :1375-1379
[8]  
BROWN LF, 1993, CANCER RES, V53, P4727
[9]   PERIPHERAL NEURITIS IN MYELOMATOSIS [J].
CROW, RS .
BRITISH MEDICAL JOURNAL, 1956, 2 (OCT6) :802-804
[10]   Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome: and a review of the literature [J].
Dispenzieri, A ;
Moreno-Aspitia, A ;
Suarez, GA ;
Lacy, MQ ;
Colon-Otero, G ;
Tefferi, A ;
Litzow, MR ;
Roy, V ;
Hogan, WJ ;
Kyle, RA ;
Gertz, MA .
BLOOD, 2004, 104 (10) :3400-3407